Pulmocef Tablets (Cefuroxime axetil)

• Composition :
  Each tablet contains Cefuroxime axetil 250/500 mg.
• Indications :
  Indicated for lower & upper respiratory tract infection, UTI, gynaecological infection, skin or soft tissue infection etc.
• Pharmacodynamics :
  The bactericidal action of cefuroxime results from inhibition of cell wall synthesis by binding to essential target proteins. Cefuroxime has good stability to bacterial beta-lactamases. Clavulanic acid binds to and inactivates them thus preventing the destruction of cefuroxime that is a substrate for this enzyme.
• Dosage and administration :
  Adults and Adolescents (13 years and older): Pharyngitis/tonsillitis (mild to moderate): 250 mg every 12 hours for 10 days. Acute bacterial maxillary sinusitis (mild to moderate):250 mg every 12 hours for 10 days. Acute bacterial exacerbations of chronic bronchitis (mild to moderate):250 or 500 mg every 12 hours for 10 days. Secondary bacterial infections of acute bronchitis: 250 or 500 mg every 12 hours for 5 to 10 days. Uncomplicated skin and skin-structure infections: 250 or 500 mg every 12 hours for 10 days. Uncomplicated urinary tract infections: 250 or 500 mg every 12 hours for 7 to 10 days. Pediatric Patients younger than 13 years (who can swallow tablets whole): Acute bacterial otitis media: 250 mg every 12 hours for 10 days. Acute bacterial maxillary sinusitis: 250 mg every 12 hours for 10 days.
• Contraindications :
  Contraindicated in patients with a known hypersensitivity (e.g., anaphylaxis) to cefuroxime axetil or to other beta-lactam antibacterial drugs (e.g., penicillins and cephalosporins).
• Precautions and warnings :
  Serious hypersensitivity (anaphylactic) reactions: In the event of a serious reaction, discontinue Pulmocef and institute appropriate therapy. Clostridium difficile-associated diarrhea (CDAD): If diarrhea occurs, evaluate patients for CDAD. The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy.
• Use in pregnancy, lactation & pediatrics :
  There are no adequate and well-controlled studies in human pregnancy and lactation. This product should only be used in pregnancy if considered essential by the physician.
• Drug interactions :
  Oral Contraceptives: Effects on gut flora may lower estrogen reabsorption and reduce efficacy of oral contraceptives. Drugs that reduce gastric acidity may lower the bioavailability of Pulmocef. Co-administration with probenecid increases systemic exposure to Pulmocef and is therefore not recommended.
• Adverse reactions :
  The most common adverse reactions for Cefuroxime axetil tablets are diarrhea, nausea/vomiting, and vaginitis (early Lyme disease).
• Therapy Area :
  Anti-Bacterials